Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

1. Hakenberg, O.W.
2. Perez-Gracia, J.L.
3. Castellano, D.
4. Demkow, T.
5. Ali, T.
6. Caffo, O.
7. Heidenreich, A.
8. Schultze-Seemann, W.
9. Sautois, B.
10. Pavlik, I.
11. Qin, A.
12. Novosiadly, R.D.
13. Shahir, A.
14. Ilaria, R.
15. Nippgen, J.